Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for GeneDx Holdings (WGS) over the last 4 years, with Sep 2025 value amounting to $26.4 million.

  • GeneDx Holdings' Accumulated Expenses rose 138.11% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 138.11%. This contributed to the annual value of $12.4 million for FY2024, which is 2.17% up from last year.
  • GeneDx Holdings' Accumulated Expenses amounted to $26.4 million in Q3 2025, which was down 6.21% from $28.1 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Accumulated Expenses registered a high of $28.1 million during Q2 2025, and its lowest value of $7.3 million during Q2 2024.
  • In the last 3 years, GeneDx Holdings' Accumulated Expenses had a median value of $13.3 million in 2023 and averaged $16.4 million.
  • In the last 5 years, GeneDx Holdings' Accumulated Expenses plummeted by 59.04% in 2024 and then skyrocketed by 285.52% in 2025.
  • GeneDx Holdings' Accumulated Expenses (Quarterly) stood at $20.1 million in 2021, then rose by 1.02% to $20.3 million in 2022, then plummeted by 40.05% to $12.2 million in 2023, then grew by 2.17% to $12.4 million in 2024, then soared by 138.11% to $26.4 million in 2025.
  • Its Accumulated Expenses was $26.4 million in Q3 2025, compared to $28.1 million in Q2 2025 and $14.0 million in Q1 2025.